Clinical trials
Plaque Psoriasis clinical trials
Below are recruiting plaque psoriasis clinical trials, each written for real people, not researchers. We’re tracking 54 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04772079RecruitingPhase 3
Test drug safety and effectiveness for youth plaque psoriasis
This study checks whether deucravacitinib works well and is safe in children and teens with moderate to severe plaque psoriasis. It also looks at drug levels in the body to help understand how the treatment behaves over time.
Ciudad Autonoma de Buenos Aires, Buenos AiresAges 4–18 - NCT06979453RecruitingPhase 3
A study of deucravacitinib for teens with plaque psoriasis
This trial tests an investigational oral medication called deucravacitinib for teenagers (adolescents) with moderate to severe plaque psoriasis. It aims to see if the drug is safe and works well.
Birmingham, AlabamaAges 12–17 - NCT07474792RecruitingPhase 2
Study of ORKA-002 for moderate-to-severe plaque psoriasis
This trial tests an investigational drug called ORKA-002 for people with moderate-to-severe plaque psoriasis. It aims to see how well different doses work and if they are safe. You may qualify if your psoriasis covers at least 10% of your body or if it has not responded well enough to other treatments.
Birmingham, AlabamaAges 18–79 - NCT06842199RecruitingPhase 3
Testing a new pill for moderate to severe plaque psoriasis
This trial tests an experimental drug called ICP-488 for people with moderate to severe plaque psoriasis. It aims to see if the drug can improve symptoms and is safe, and may be an option if you need stronger treatment than creams or light therapy.
Hefei, AnhuiAges 18–75 - NCT04537689RecruitingPhase 4
Test ixekizumab and stopping it in plaque psoriasis
This study looks at how well ixekizumab (an injection medication) works for moderate-to-severe plaque psoriasis, and what happens when the treatment is withdrawn. It may help you learn whether stopping the medicine is safe and how skin disease outcomes change over time.
Outram ParkAges 22–90 - NCT07449702RecruitingPhase 2
Long-term safety study of ORKA-001 for plaque psoriasis
This study is a continuation for people who already took ORKA-001 for plaque psoriasis and did well. It tests whether staying on the medicine keeps helping without any new safety concerns.
Fountain Valley, CaliforniaAges 18 years+ - NCT06058546RecruitingPhase 2
Jiuweihuaban pill for plaque psoriasis
This trial tests a Chinese herbal pill for people with mild-to-moderate plaque psoriasis. The pill is meant to reduce redness, scaling, and inflammation by targeting a specific pattern in traditional Chinese medicine.
BeijingAges 18–65 - NCT07251998RecruitingPhase 2
A study of ICP-332 for moderate to severe plaque psoriasis
This trial tests an oral medication called ICP-332 versus a placebo (a pill with no active drug) for people with moderate to severe plaque psoriasis. The goal is to see if ICP-332 can improve skin symptoms and be safe.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07326813RecruitingPhase 3
Testing D-2570 for moderate to severe plaque psoriasis
This trial tests if a new oral medication called D-2570 can safely and effectively treat moderate to severe plaque psoriasis. It may be an option if your psoriasis covers a large area and has been stable for at least 6 months.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07234591Recruiting
Study of an oral medication for moderate to severe plaque psoriasis
This study tests an experimental oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing psoriasis symptoms.
ShanghaiAges 18–70 - NCT07130604RecruitingPhase 3
Testing a new pill for moderate to severe plaque psoriasis
This trial tests an experimental pill called D-2570 for people with moderate to severe plaque psoriasis. It aims to see if the pill can safely improve skin symptoms like redness, scaling, and thickness.
Beijing, Beijing MunicipalityAges 18–70 - NCT07129382RecruitingPhase 1/Phase 2
Study of CS32582 for moderate to severe plaque psoriasis
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
Beijing, Beijing MunicipalityAges 18–70 - NCT07039110Recruiting
Risankizumab for psoriasis: quality of life study
This study looks at how risankizumab (Skyrizi) affects the quality of life for adults with moderate-to-severe plaque psoriasis. It is an observational study, meaning no new treatments are given—researchers simply follow patients who are already being treated with risankizumab as part of their regular care.
Calgary, AlbertaAges 18 years+ - NCT07250802RecruitingPhase 3
Long-term study of zasocitinib for children with plaque psoriasis
This trial tests a daily pill (zasocitinib) for children and teens with moderate to severe plaque psoriasis that hasn't been controlled by other treatments. It aims to see if the pill can safely improve skin symptoms over a long period.
Chula Vista, CaliforniaAges 4–17 - NCT07024602RecruitingPhase 1
Testing ASC50 tablets for plaque psoriasis
This study tests an investigational tablet called ASC50 for plaque psoriasis. It aims to see if it is safe and works well for people with this skin condition.
Miami, FloridaAges 18–65 - NCT07038720RecruitingPhase 1
Testing an experimental oral tablet for moderate to severe psoriasis
This early-phase study tests an experimental oral tablet (UA026) in people with moderate to severe plaque psoriasis. The purpose is to see how safe and effective the drug is, and how it works in the body.
Hangzhou, ZhejiangAges 18–55 - NCT06030076Recruiting
Switching to tildrakizumab for moderate to severe psoriasis
This trial is for adults with moderate to severe plaque psoriasis who are currently on a biologic treatment (like Humira, Stelara, or Cosentyx) and are switching to tildrakizumab. It looks at how your quality of life and symptoms change after the switch.
Graz, StyriaAges 18 years+ - NCT07672561RecruitingPhase 3
Testing a new pill for moderate to severe plaque psoriasis
This study tests an experimental pill called WD-890 to see if it can help people with moderate to severe plaque psoriasis. The pill is compared to a placebo (a pill with no medicine) to check if it is safe and works well.
Nanjing, JiangsuAges 18–75 - NCT06696417Recruiting
Testing vunakizumab for moderate to severe plaque psoriasis
This study tests a new drug called vunakizumab to see if it is safe and works well for people with moderate to severe plaque psoriasis. If you have not used biologic treatments before and meet other health requirements, you may be able to join.
Shenyang, LiaoningAges 18 years+ - NCT06382987Recruiting
Comparing deucravacitinib vs apremilast for plaque psoriasis
This study compares two oral medications, deucravacitinib and apremilast, for adults with plaque psoriasis in Japan. It looks at how well each drug works in real-world use.
Minato-ku, TokyoAges 18 years+ - NCT07545902Recruiting
Urea-based creams for plaque and palm-sole psoriasis
This study tests two medicated creams containing urea (a natural moisturizing ingredient) to treat psoriasis on the skin and on the palms and soles of the feet. The creams may help reduce flaking, scaling, and irritation in people with mild psoriasis.
Chieti, ItaliaAges 18–65 - NCT07780929Recruiting
Study of XJH05 ointment for mild-to-moderate plaque psoriasis
This trial tests a new ointment (XJH05) for people with mild-to-moderate plaque psoriasis. It aims to see if this treatment helps reduce symptoms and is safe for topical use.
Xi'an, ShaanxiAges 18–65 - NCT07362017RecruitingPhase 3
Ponesimod for moderate to severe plaque psoriasis
This trial tests an investigational drug called ponesimod for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at improving skin symptoms.
Glendale, ArizonaAges 18–65 - NCT07733089RecruitingPhase 1
Testing a new psoriasis drug for safety and effect
This trial tests a new study drug (ZP9830) to see if it is safe and works well for people with plaque psoriasis. You would receive the treatment for 8 weeks, and the study will check how your skin responds.
Leiden, South HollandAges 18–60
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Plaque Psoriasis trials by city
Studies with a site in or near these metro areas.
Plaque Psoriasis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for plaque psoriasis?
- Yes. Clin2 currently lists 54 recruiting plaque psoriasis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a plaque psoriasis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a plaque psoriasis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.